About AVIA Biosystems
AVIA Biosystems is a company based in Norton (United States) founded in 2012 was acquired by Unchained Labs in June 2015.. AVIA Biosystems has raised $1.1 million across 5 funding rounds from investors including HHS and Unchained Labs. AVIA Biosystems offers products and services including ICD Systems and Model 2304 ICD Systems. AVIA Biosystems operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Norton, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avia Biosystems, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.1 M (USD)
in 5 rounds
-
Latest Funding Round
$207.38 K (USD), Grant
Mar 01, 2015
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Unchained Labs
(Jun 04, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AVIA Biosystems
AVIA Biosystems offers a comprehensive portfolio of products and services, including ICD Systems and Model 2304 ICD Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Measures protein denaturation with minimal samples for biologics testing.
Screens buffers and excipients for protein stability optimization.
Funding Insights of AVIA Biosystems
AVIA Biosystems has successfully raised a total of $1.1M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $207.38 thousand completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $207,380
-
First Round
First Round
(17 Jan 2012)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2015 | Amount | Grant - AVIA Biosystems | Valuation |
investors |
|
| Jan, 2014 | Amount | Seed - AVIA Biosystems | Valuation |
investors |
|
| May, 2012 | Amount | Grant - AVIA Biosystems | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AVIA Biosystems
AVIA Biosystems has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Unchained Labs. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Multiplex protein stability platform for biologics is developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AVIA Biosystems
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AVIA Biosystems
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avia Biosystems Comparisons
Competitors of AVIA Biosystems
AVIA Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein-based assays are developed for life science research.
|
|
| domain | founded_year | HQ Location |
A proteomics platform is developed for analyzing the human proteome.
|
|
| domain | founded_year | HQ Location |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| domain | founded_year | HQ Location |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| domain | founded_year | HQ Location |
Digital platform transforming the delivery of biologic medicines
|
|
| domain | founded_year | HQ Location |
Provider tools to help researchers with protein analysis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about AVIA Biosystems
When was AVIA Biosystems founded?
AVIA Biosystems was founded in 2012.
Where is AVIA Biosystems located?
AVIA Biosystems is headquartered in Norton, United States.
Is AVIA Biosystems a funded company?
AVIA Biosystems is a funded company, having raised a total of $1.1M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.39M, raised on Jan 17, 2012.
What does AVIA Biosystems do?
The ICD system makes possible the routine measurement of protein stability under denaturing conditions. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The company has a device developed to facilitate the formulation of biologics in a safe and stable form, the system uses intrinsic or extrinsic fluorescence to monitor the conformational changes associated with protein unfolding (denaturation) and automatically generates complete protein stability curves. In pharmaceutical discovery and development settings, large numbers of constructs or formulations need to be rapidly and easily compared (rank-ordered) for stability. For these applications, automated chemical denaturation provides the most powerful and convenient means to assess protein stability.
Who are the top competitors of AVIA Biosystems?
AVIA Biosystems's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
What products or services does AVIA Biosystems offer?
AVIA Biosystems offers ICD Systems and Model 2304 ICD Systems.
Who are AVIA Biosystems's investors?
AVIA Biosystems has 2 investors. Key investors include HHS, and Unchained Labs.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.